Showing results (51-60 of 4,635) with videos related to
Sort By:
Pageof 464
Anti-Cancer Drugs|August 1, 1997
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitroM Stahl, S Kasimir-Bauer, A HarstrickAnti-Cancer Drugs|July 1, 1997
Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancerH Cortes-Funes, C Martin, R Abratt, et al.Anti-Cancer Drugs|July 1, 1997
Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchangeM Hamatake, T Andoh, R IshidaAnti-Cancer Drugs|June 23, 1998
Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patientsA Zaniboni, A Bolognesi, E Arnoldi, et al.Anti-Cancer Drugs|June 23, 1998
Phase II study of paclitaxel in pretreated advanced gastric cancerS Cascinu, F Graziano, N Cardarelli, et al.Anti-Cancer Drugs|June 23, 1998
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugsJ Gehl, T Skovsgaard, L M MirAnti-Cancer Drugs|June 23, 1998
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming unitsH Soda, E Raymond, S Sharma, et al.Anti-Cancer Drugs|July 20, 2016
The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiationBernard Tawfik, Ali A Mokdad, Prachi M Patel, et al.Anti-Cancer Drugs|May 2, 2015
Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapyJohn P Micha, Aaron F Sassoon, Humberto Wong, et al.Anti-Cancer Drugs|January 22, 1998
Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implicationsS R JohnstonPageof 464